188345-71-3

Usage

Uses

Used in Organic Synthesis:
Tert-Butyl2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate is used as a key intermediate in organic synthesis for its ability to participate in numerous chemical reactions, facilitating the creation of complex organic molecules.
Used in Pharmaceutical Research:
In pharmaceutical research, Tert-Butyl2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate is employed as a building block for the development of new drugs. Its unique structure allows for the exploration of novel chemical pathways and the synthesis of bioactive compounds with potential therapeutic applications.
Used in Drug Discovery:
Tert-Butyl2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate is utilized in drug discovery as a component that can be modified to create a diverse range of pharmaceutically relevant molecules. Its reactivity and structural features make it a promising candidate for the design of new drugs with improved efficacy and selectivity.
Used in the Production of Pharmaceuticals:
Tert-Butyl2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate is also used in the actual production of pharmaceuticals, where its unique chemical properties contribute to the synthesis of bioactive compounds that can be used for the treatment of various diseases and conditions.
Used in Bioactive Compounds Synthesis:
Tert-Butyl2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate is used as a precursor in the synthesis of bioactive compounds, which are essential for the development of new therapeutic agents and the enhancement of existing ones.

InChI:InChI=1/C11H17NO2/c1-11(2,3)14-10(13)12-7-8-4-5-9(12)6-8/h4-5,8-9H,6-7H2,1-3H3

Upstream product

• 77-73-6 bi(cyclopentadiene) 
• 24424-99-5 di-tert-butyl dicarbonate 
• 49805-30-3 2-azabicyclo[2.2.1.]hept-5-en-3-one 
• 63882-16-6 2-Aza-bicyclo[2.2.1]hept-5-ene; hydrochloride 
• 244630-13-5 3-(tert-butoxycarbonyl)-3-azatricyclo[2.2.1.0^2,6]heptan-5-ol 
• 219325-28-7 N-tert-butyloxycarbonyl-3-oxa-8-azatricyclo[3.2.1.0^2,4]octane 
• 192118-47-1 tert-butyl 7-azabicyclo[2.2.1]hept-2-ene-7-carboxylate 
• 50-00-0 formaldehyd 
• 542-92-7 cyclopenta-1,3-diene 
• 6671-85-8 2-azabicyclo[2.2.1]hept-5-ene 

Downstream Products

• 848591-68-4 tert-butyl 3-benzyl-3,6-diazabicyclo[3.2.1]octane-6-carboxylate 
• 1058737-58-8 tert-butyl 2,4-bis(hydroxymethyl)pyrrolidine-1-carboxylate 
• 286947-23-7 3-benzyl-3,6-diazabicyclo[3.2.1]octane 
• 198835-06-2 tert-butyl 5-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1932285-09-0 tert-butyl 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1099570-25-8 tert-butyl 6-hydroxy-2-azabicyclo[2,2,1]heptane-2-carboxylate 
• 207405-60-5 (1R,4R)-1,1-Dimethylethyl 5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 64769-66-0 cis-pyrrolidine-2,4-dicarboxylic acid 
• 851526-82-4 1-(3-Benzyl-3,6-diazabicyclo[3.2.1]oct-6-yl)-2,2,2-trifluoro-ethanone 
• 194032-49-0 tert-butyl 3,6-diazabicyclo [3.2.1]octane-6-carboxylate 

Relevant academic research and scientific papers

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

AMIDES OF DIAZABICYCLOOCTANES AND USES THEREOF

The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).

Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists

Orexins are neuropeptides that regulate wakefulness and arousal. Small molecule antagonists of orexin receptors may provide a novel therapy for the treatment of insomnia and other sleep disorders. In this Letter we describe the design and synthesis of con

HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS

A compound of Formula 1: A-C(O)-Cy, wherein A is a diazabicyclic core, containing 7, 8, or 9 ring atoms, and selected from the following: 2,6-diazabicyclo[3.2.0]heptane; 3,6-diazabicyclo[3.ZO]heptane; 2,7-diazabicyclo[4.2.0]octane; 3,7-diazabicyclo[4.2.0]octane; 3,8-diazabicyclo[4.2.0]octane; 2,7-diazabicyclo[3.3.0]octane; 2,7-diazbicyclo[4.3.0]nonane; 2,8-diazbicyclo[4.3.0]nonane; 3,7-diazabicyclo[4.3.0]nonane; 3,8-diazabicyclo[4.3.0]nonane; 3,9-diazabicyclo[4.3.0]nonane; 2,6-diazabicyclo[3.2.1 ]octane; 3,6-diazabicyclo[3.2.1]octane; wherein the diazabicycle is attached as a radical to the depicted carbonyl via either one of the two ring nitrogen atoms, such that the carbonyl forms an amide bond with the ring nitrogen; Cy is a heteroaryi group; The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α402 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds are believed to: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects, namely side effects such as significant Increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle.

Structure-activity studies and analgesic efficacy of N-(3-pyridinyl)- bridged bicyclic diamines, exceptionally potent agonists at nicotinic acetylcholine receptors

A series of exceptionally potent agonists at neuronal nicotinic acetylcholine receptors (nAChRs) has been investigated. Several N-(3-pyridinyl) derivatives of bridged bicyclic diamines exhibit double-digit-picomolar binding affinities for the α4β2 subtype, placing them with epibatidine among the most potent nAChR ligands described to date. Structure-activity studies have revealed that substitutions, particularly hydrophilic groups in the pyridine 5-position, differentially modulate the agonist activity at ganglionic vs central nAChR subtypes, so that improved subtype selectivity can be demonstrated in vitro. Analgesic efficacy has been achieved across a broad range of pain states, including rodent models of acute thermal nociception, persistent pain, and neuropathic allodynia. Unfortunately, the hydrophilic pyridine substituents that were shown to enhance agonist selectivity for central nAChRs in vitro tend to limit CNS penetration in vivo, so that analgesic efficacy with an improved therapeutic window was not realized with those compounds.

Substituted diazabicycloakane derivatives

Compounds of formula (I) Z-Ar1—Ar2??(I) wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from an unsubstituted or substituted 5-membered heteroaryl ring; an unsubstituted or substituted 6-membered heteroaryl ring; 3,4-(methylenedioxy)phenyl; and phenyl substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

Development of two processes for the synthesis of bridged azabicyclic systems: Intermolecular radical addition-homoallylic rearrangements leading to 2-azanorborn-5-enes and neophyl-type radical rearrangements to 2-azabenzonorbornanes

Radical thiol additions to 7-azanorbornadienes give 7-thio-substituted 2-azanorbornenes and Barton deoxygenations of 7-azabenzonorbornanols give 2-azabenzonorbornanes. The processes both involve novel nitrogen-directed radical rearrangements. The kinetics and mechanisms of the reactions are also discussed.

6-Substituted 2-azabicyclo[2.2.1]hept-5-enes by nitrogen-directed radical rearrangement: Synthesis of an epibatidine analogue with high binding affinity at the nicotinic acetylcholine receptor

Base-induced isomerisation of epoxide 13 gives an azanortricyclanol 17 which is a precursor for a novel free-radical induced rearrangement to 6-substituted 2-azabicyclo[2.2.1]hept-5-enes 28-31. Compound 31 undergoes selective exo-face hydrogenation to giv

Heterocyclic compounds

The present invention provides heterocyclic 2-aza-bicyclo[2.2.1]heptane compounds which are useful for modulating a muscarinic ptor.